These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33571026)

  • 1. Cost-Effectiveness Analysis of Ginkgolide Injection in the Treatment of Ischemic Stroke Based on a Randomized Clinical Trial.
    Xiang Y; Yang N; Guo Z; Zhou L; Guo JJ; Hu M
    J Altern Complement Med; 2021 Apr; 27(4):331-341. PubMed ID: 33571026
    [No Abstract]   [Full Text] [Related]  

  • 2. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective.
    Zhang L; Lin Z; Yin H; Liu J; Xuan J
    Clin Ther; 2018 Dec; 40(12):2125-2137. PubMed ID: 30470579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke.
    Pan Y; Wang A; Liu G; Zhao X; Meng X; Zhao K; Liu L; Wang C; Johnston SC; Wang Y; Wang Y;
    J Am Heart Assoc; 2014 Jun; 3(3):e000912. PubMed ID: 24904018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases.
    Lee MC; Liao CT; Toh HS; Chou CC; Chang WT; Chen ZC; Wu WS; Yu T; Strong C
    Cardiovasc Drugs Ther; 2021 Jun; 35(3):539-547. PubMed ID: 32910340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of endovascular therapy for acute ischemic stroke with large infarct in China.
    Pan Y; Huo X; Jin A; Nguyen TN; Ma G; Tong X; Zhang X; Gao F; Ma N; Mo D; Ren Z; Wang Y; Miao Z
    J Neurointerv Surg; 2024 Apr; 16(5):453-458. PubMed ID: 37328189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of tirofiban for acute ischemic stroke without large or medium-sized vessel occlusion: A Markov modelling analysis from the Chinese and United States perspectives.
    Wang L; Zeng Y; Zhou L; Xu P; Guo X; Xie Y; Cai J; Pan M; Tang J; Gong Q; Su R; Liu Y; Lou Y
    PLoS One; 2024; 19(2):e0297939. PubMed ID: 38363737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Mechanical Thrombectomy More Than 6 Hours After Symptom Onset Among Patients With Acute Ischemic Stroke.
    Peultier AC; Pandya A; Sharma R; Severens JL; Redekop WK
    JAMA Netw Open; 2020 Aug; 3(8):e2012476. PubMed ID: 32840620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effective analysis of clopidogrel versus aspirin for high risk patients with established peripheral arterial disease in China.
    Lin Z; Zhang L; Yang X; Liu L; Xuan J
    J Med Econ; 2020 Jun; 23(6):659-666. PubMed ID: 31999196
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness analysis of polymyxin B versus colistin for treating patients with carbapenem-resistant gram-negative bacterial infections.
    Wang Y; Yu L; Zhu J; Liang G; Liu J; Zheng Y; Zhao Y; Yu Z
    Sci Rep; 2024 Oct; 14(1):23635. PubMed ID: 39384871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
    Schleinitz MD; Heidenreich PA
    Ann Intern Med; 2005 Feb; 142(4):251-9. PubMed ID: 15710958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Sep; 10(5):331-42. PubMed ID: 22853743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
    Main C; Palmer S; Griffin S; Jones L; Orton V; Sculpher M; Henderson R; Sudlow C; Hawkins N; Riemsma R
    Health Technol Assess; 2004 Oct; 8(40):iii-iv, xv-xvi, 1-141. PubMed ID: 15461878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 17. Economic Evaluation of Ticagrelor Plus Aspirin Versus Aspirin Alone for Acute Ischemic Stroke and Transient Ischemic Attack.
    Chen J; Ji L; Tong X; Han M; Zhao S; Qin Y; He Z; Jiang Z; Liu A
    Front Pharmacol; 2022; 13():790048. PubMed ID: 35370758
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic evaluation of intravenous alteplase for stroke with the time of onset between 4.5 and 9 hours.
    Chen J; Liang X; Tong X; Han M; Ji L; Zhao S; Hu Z; Liu A
    J Neurointerv Surg; 2023 Jan; 15(1):46-51. PubMed ID: 35074896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2006; 24(7):709-26. PubMed ID: 16802846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack.
    Cai Z; Cai D; Wang R; Wang H; Yu Z; Gao F; Liu Y; Kang Y; Wu Z
    Sci Rep; 2021 Apr; 11(1):7383. PubMed ID: 33795788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.